Why do some cancer patients relapse even after surgery, chemo, and radiation — while others recover long-term?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the missing link most oncologists never talk about: DAMPS — Damage Associated Molecular Patterns. These are the danger signals cancer cells release when they die, and they determine whether your immune system wakes up… or whether the cancer becomes more resistant.
You’ll learn why too much chemotherapy or radiation can release uncontrolled DAMPS, triggering inflammation, mutations, and relapse — especially in late-stage disease. And you’ll discover how microdosed, genetically targeted chemotherapy, combined with immune profiling and spatial biology, activates DAMPS in the right way to train your immune system for long-term control.
Dr. Prato walks through how adaptive monitoring (CTCs, ctDNA, methylation), nutritional changes, sleep, inflammation control, phytotherapy, and cellular biologics all work together to keep immune signals tuned and prevent relapse.
🎯 What You’ll Learn in This Episode:
• What DAMPS are — and why they determine relapse or recovery
• How high-dose chemo/radiation can trigger resistance and mutations
• Why microdosed, targeted chemotherapy activates the “right” immune signals
• How NK cells, dendritic cells & immune profiling enhance DAMPS response
• How sleep, diet, inflammation markers, and stress impact immune signaling
• Why liquid biopsies (CTCs, ctDNA, methylation) reveal relapse early
• How personalized dosing prevents overactivation and immune collapse
• Why the future of cancer care is immune-centric precision oncology
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“When you align treatment with immune signaling, you stop fighting cancer — you teach your body to win.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493
